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While emerging evidence indicates that the pathogenesis of Parkinson’s disease is 
strongly correlated to the accumulation1,2 and transmission3,4 of α-synuclein (α-syn) aggregates 
in the midbrain, no anti-aggregation agents have been successful at treating the disease in the 
clinic. Here we show that graphene quantum dots (GQDs) inhibit fibrillization of α-syn and 
interact directly with mature fibrils, triggering their disaggregation. Moreover, GQDs can rescue 
neuronal death and synaptic loss, reduce Lewy body and Lewy neurite formation, ameliorate 
mitochondrial dysfunctions, and prevent neuron-to-neuron transmission of α-syn pathology 
provoked by α-syn preformed fibrils (PFFs)5,6. We observe that in vivo, GQDs penetrate the 
blood-brain barrier (BBB) and protect against dopamine neuron loss induced by α-syn PFFs, 
Lewy body/Lewy neurite pathology, and behavioural deficits (Supplementary Fig. 1). 
Following the synthesis and analysis of GQDs (Supplementary Fig. 2a-c,e), the potential 
role of GQDs in inhibiting α-syn fibrillization and disaggregating fibrils was preliminarily 
investigated (Fig. 1a). In the absence of GQDs, α-syn monomers are assembled into mature 
fibrils as assessed by thioflavin T (ThT) fluorescence (Fig. 1b), turbidity assays (Fig. 1c), and 
transmission electron microscopy (TEM) analysis (Fig. 1d). In contrast, the same assessments 
display that GQDs predominantly inhibit α-syn fibrillization. Moreover, GQDs induce 
dissociation of α-syn fibrils into short fragments (Fig. 1e-i, supplementary Fig. 3a), where the 
average length of the fragments shortens from 1 m to 235 and 70 nm after 6 and 24 hours, 
respectively (Fig. 1g,i). The average number of the shortened fragments is increased during the 
first 24 hours of incubation, suggesting that the fibrils are dissociated from the inner parts (Fig. 
1h). However, the number of fragments starts to decrease at day 3 and is no longer detectable at 
day 7, indicating complete dissociation of fibrils in the course of time (Fig. 1i). Time-dependent 
atomic force microscopy (AFM) images show the same dissociation process, where GQDs and 
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fibrils can be differentiated by their distinguishing height profiles (Supplementary Fig. 3b). Dot-
blot assay and blue native polyacrylamide gel electrophoresis (BN-PAGE) analysis also reveal 
that incubation with GQDs results in gradual reduction of fibrils in a time-dependent manner 
(Fig. 1j,k). Similar effects of GQDs are observed for sonicated α-syn PFFs, which produced 
higher population of monomers as a function of the incubation period (Supplementary Fig. 4a-c).  
To visualise the interaction between GQDs and α-syn fibrils, GQDs were functionalised 
with PEGylated biotin (Supplementary Fig. 2d-g). As detected with streptavidin tagged ultra-
small gold particles using TEM, the direct binding between GQDs and α-syn fibrils was 
visualised (Fig. 2a,b). Two-dimensional 1H-15N hetero-nuclear single-quantum coherence 
correlation (HSQC) NMR spectroscopy was utilised to further analyse the interaction site of 15N-
labelled α-syn7,8 for GQDs and their molecular interactions at the residue level in solution. The 
co-incubation of GQDs produced many residues with large chemical shifts and entirely 
disappeared residues (Supplementary Fig. 5). The disappeared residues are centred on the N-
terminal region, implying that the initial binding between GQDs and α-syn is largely driven by 
the charge interaction between GQDs’ negatively charged carboxyl groups (Supplementary Fig. 
2e) and the positively charged region of α-syn (Fig. 2c).  
To better understand and elucidate the mechanism of α-syn fibril dissociation by GQDs, 
200 ns molecular dynamics (MD) simulation was performed. The structure of α-syn fibril was 
adopted from the recently reported ssNMR (solid-state nuclear magnetic resonance) structure of 
pathologic human α-syn9. To facilitate the simulation process, only the non-amyloid- 
component (NAC) domain (residue 71 to 82) was taken as it is essential for α-syn fibrillization10. 
Following the instantaneous binding between GQDs and the N-terminal cross-β part of α-syn at 
1 ns, the β-sheet structure of the outer monomer is completely destroyed after 50 ns; its C-
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terminal part is released from the core and interacts with the opposite plane of GQDs (Fig. 2d). 
The time-dependent secondary structure plot, calculated by the dictionary of secondary structure 
of proteins (DSSP) algorithm, also presents decrease in the β-sheet component of the outer 
monomer from 50 ns onwards, indicating a critical structural disruption in the fibril (Fig. 2f). For 
further analysis, the changes in the root-mean-square deviation (RMSD) of atomic positions, 
solvent accessible surface area (SASA), and the interaction energies of the fibril were plotted 
against time (Fig. 2e). While massive changes in the RMSD and SASA values are observed after 
50 ns, the changes in the total potential energy (∆Utot) show a slight, yet continuous decline. It is 
confirmed that the major stabilising/dissociation force is attributed to strong hydrophobic 
interactions, as the changes in the van der Waals energy (∆Evan) show a decline and the 
electrostatic energy (∆Eelec) remains steady. The results are consistent with the 65 ns snapshot, 
which shows strong hydrophobic interactions between GQDs’ basal plane and valine residues 
(Fig. 2d). To further analyse the changes in the secondary structure of α-syn fibrils, circular 
dichroism (CD) spectra were obtained and the fractional secondary structures were analysed 
using the algorithm of CONTIN/LL11,12 (Fig. 2g,h). After 7 days, changes in the secondary 
structure were observed, where the -sheet component decreased from 53.3±3.5% to 29.8±3.4% 
and the α-helix / random coil components increased from 4.2±1.2% to 19.8±1.5% and 20.1±5.7% 
to 24.6±3.6%, respectively. Collectively, the interaction between GQDs and α-syn is initiated by 
the charge interactions, and fibril dissociation is driven chiefly by hydrophobic interactions, 
accompanied by the structural changes.  
Based on these results, GQDs’ potential role in preventing α-syn PFFs-induced 
pathology was explored in primary neurons. α-syn PFFs treatment leads to critical cell death as 
assessed by various cell viability assays including terminal deoxynucleotidyl transferase dUTP 
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nick end labelling (TUNEL) (Fig. 3a and Supplementary Fig. 6a), alamarBlue (Fig. 3b), lactate 
dehydrogenase (LDH) (Fig. 3c), and neurite outgrowth assays (Supplementary Fig. 6b-d). In 
contrast, the presence of GQDs reduces α-syn PFFs-induced cell toxicity in the same 
assessments. In addition, treatment of α-syn PFFs leads to reduction in synaptic proteins such as 
SNAP25 and VAMP2, suggesting severe dysfunction in neuronal networks5. Importantly, GQDs 
restore the reduced synaptic protein levels provoked by α-syn PFFs (Supplementary Fig. 6e-g). 
Mitochondrial dysfunction is another major pathological hallmark during the progression of PD13. 
The effect of GQDs on mitochondrial dysfunction and subsequent cellular respiration was thus 
investigated by performing oxidative stress marker 8-hydroxyguanosine (8-OHG) staining, 
mitochondrial complex I activity assay, MitoTracker staining, TEM analysis, and seahorse assay 
(Supplementary Fig.7). While the treatment of α-syn PFFs causes mitochondrial damages 
characterised by shrinkage, decreased oxygen consumption rate, and elevated reactive oxygen 
species (ROS) levels in neurons, the addition of GQDs ameliorates these adverse effects. 
Next, the role of GQDs on α-syn PFFs-induced LBs/LNs-like pathology was evaluated. 
After 7 days of α-syn PFFs treatment, accumulation of α-syn in the sodium dodecyl sulphate 
(SDS)-insoluble fraction was analysed by Western blot, which shows decreased phosphorylated 
α-syn (p-α-syn) accumulation with GQDs (Fig. 3d,e). In addition, p-α-syn immunoreactivity is 
increased in primary neurons by α-syn PFFs, whereas it is barely detectable in primary neurons 
treated with GQDs as assessed by α-syn phosphoserine 129 immunostaining (Fig. 3f,g). To 
investigate the effect of treatment time on α-syn pathology, GQDs were treated simultaneously 
with and 3 days pre- / post α-syn PFFs additions. While the toxicity amelioration and inhibition 
effects on p-α-syn accumulation were slightly weaker when GQDs were treated 3 days after α-
syn PFFs injection, the collective results practically show consistent effects (Supplementary Fig. 
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8a-f). To verify the cellular localisation of GQDs’ inhibitory effects, GQDs, α-syn PFFs, and the 
lysosome were distinctively labelled with fluorescent probes for live imaging (Supplementary 
Fig. 8g,h). As shown from the time-course snapshots, the fluorescence signals for α-syn PFFs 
and GQDs are co-localised within the lysosome, where the signal for α-syn PFFs gradually 
decreases and that of GQDs increases with time. It can be presumed that both GQDs and α-syn 
PFFs are endocytosed, and the disaggregation of fibrillized α-syn takes place in the lysosome by 
surrounding GQDs.  
One of the most key features of the α-syn PFFs neuron model is neuron-to-neuron 
transmission of pathologic α-syn aggregates5. To examine the effect of GQDs, a triple-
compartment microfluidic culture device was employed, where transmission between neurons 
takes place sequentially from C1 to C3 (Fig. 3h). At 14 days post-α-syn PFFs treatment, the 
levels of p-α-syn were visualised by immunostaining in all test chambers. The levels of p-α-syn 
immunoreactivity are greatly reduced in C2 and C3 in the presence of GQDs in C1, which 
suggests that GQDs prevent the seeds of endogenous α-syn from forming aggregates (Fig. 3i,j). 
Also, the levels of p-α-syn immunoreactivity are lowered in C2 and C3 when GQDs are added to 
C2; GQDs block the transmission of pathologic α-syn to the neighbouring neurons.  
To address whether GQDs possess neuroprotective effects against α-syn PFFs-induced 
transmission and toxicity in vivo, α-syn PFFs were stereotaxically injected into the striatum of 
wild type (WT) mice and GQDs were biweekly administered via intraperitoneal (i.p.) injection 
(Fig. 4a). Foremost, we sought to verify the blood-brain barrier (BBB) permeability of GQDs by 
employing an in vitro BBB model14 (Supplementary Fig. 9a,b). The formation and functionality 
of the BBB model were subsequently confirmed by measuring the transepithelial electrical 
resistance (TEER) and dextran fluorescence intensity (Supplementary Fig. 9c,d). The in vitro 
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permeability of GQDs was then ascertained by measuring the fluorescence intensity on the brain 
side. Intriguingly, the fluorescence signal gradually increased with time, and showed 100% 
permeability after 24 hours (Supplementary Fig. 9e). To corroborate the penetration process 
visually, GQDs-biotin was utilised and linked to streptavidin-quantum dots for live fluorescence 
imaging. Prior to the study, the functional behaviours of GQDs-biotin were assessed, which 
exhibited similar BBB penetration rates and fibril dissociation effects as those of pristine GQDs 
(Supplementary Fig. 9e-g). Live fluorescence imaging shows that GQDs-biotin complex is 
localised in the lysosome of both BMEC and astrocytes, and disappears through the exosome 
(Supplementary Fig. 9h,i). It suggests that GQDs are endocytosed into BMEC on the blood side 
and released, which are subsequently endocytosed by astrocytes on the brain side and released 
through the exosome. In vivo permeability of the BBB was studied by employing GQDs-biotin 
for immunohistochemical analysis of the brain. Considerable amount of GQDs-biotin was 
detected in the entire central nervous system (CNS) region including the olfactory bulb, 
neocortex, midbrain, and cerebellum after i.p. injection, indicating that GQDs have the ability to 
penetrate the BBB in vivo as well (Supplementary Fig. 9j-n).  
At 180 days post-α-syn PFFs injection, decreased tyrosine hydroxylase (TH)- and Nissl-
positive neurons in the substantia nigra (SN) are observed in WT mice. On the other hand, mice 
administered with GQDs are protected against α-syn PFFs-induced loss of dopaminergic neurons 
(Fig. 4b,c). Furthermore, α-syn PFFs provoke a loss of TH-positive striatal fibre neurons, while 
GQDs prevent the loss in the striatum as well (Fig. 4d,e). Finally, changes in the behavioural 
deficits were assessed by the cylinder and pole tests. Mice with GQDs injection exhibited 
alleviated motor deficit, showing balanced use of both forepaws and decreased pole descending 
time, respectively in the cylinder and pole tests (Fig. 4f,g). 
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The levels of p-α-syn, a marker of LBs/LNs were subsequently visualised in the striatum 
and SN of α-syn PFFs-injected mice. While stereotaxically injected α-syn PFFs provoke 
accumulation of p-α-syn in the striatum and SN, the administration of GQDs reduces the p-α-syn 
levels (Fig. 4h,i). The injection of α-syn PFFs in the striatum also leads to propagation of α-syn 
aggregates throughout the CNS region, whereas GQDs inhibits the transmission of pathological 
α-syn (Fig. 4j). In addition, GQDs injection ameliorates α-syn PFFs-induced gliosis in the SN 
accompanying the decreased microglia density and glial fibrillary acidic protein (GFAP) levels in 
astrocytes (Supplementary Fig.10). To further corroborate GQDs’ therapeutic potential against 
transgenic in vivo PD model, 6-month human A53T α-syn transgenic mice15 were biweekly 
administered with GQDs for 4 months (Supplementary Fig. 11a). Similar to the α-syn PFFs-
induced model, GQDs administration reduces the p-α-syn levels in the CNS region, 
(Supplementary Fig. 11b-d) as well as the microglia density and GFAP levels in astrocytes in the 
transgenic model (Supplementary Fig. 11h-k). GQDs treatment also reduces the α-syn aggregates 
induced by overexpression of human A53T α-syn in HEK293 cells16 (Supplementary Fig. 11l,m). 
GQDs alleviate the behavioural defects in the hA53T α-syn Tg mice as well, monitored by the 
pole and clasping tests (Supplementary Fig. 11e-g). It must be noted that there is no loss of 
dopamine neurons, glial cells activation, behavioural abnormalities, and organ damages in mice 
with 6 months of prolonged GQDs injection, demonstrating that GQDs manifest no appreciable 
long-term in vitro and in vivo toxicity and can be cleared from the body and excreted into urine 
(Supplementary Fig. 12). 
A few previous reports have discussed graphene oxides’ (GOs) and GQDs potential 
therapeutic role against Alzheimer’s disease (AD) by inhibiting the fibrillization of beta-amyloid 
(A) peptides17-19. In addition, computational evidence suggests hydrophobic graphene sheet 
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could cause destruction of amyloid fibrils20. To compare the therapeutic efficacy of GQDs with 
the previous studies, nano-sized GOs (nano-GOs) ranging 5 ~ 20 nm and reduced GQDs (rGQDs) 
were prepared (Supplementary Fig. 13a,b). As shown from the FT-IR spectra, pristine GQDs 
exhibit predominant carboxyl groups, while nano-GOs and rGQDs show much less carboxyl 
group: aromatic carbon double bond ratios. The difference in the carboxyl functional group 
contents was directly reflected in cell viability assays, where nano-GOs and rGQDs show serious 
in vitro toxicities unlike GQDs (Supplementary Fig. 13c,d). Moreover, nano-GOs and rGQDs 
exhibit considerably weaker fibril-dissociation effects than GQDs (Supplementary Fig. 13e-g). 
This can be presumably attributed to the presence of less carboxyl functional groups as well, as 
we have verified from the 1H-15N HSQC analysis that the positively charged N-terminal region is 
the initial, yet the chief binding site with GQDs. It must be also noted that the BBB permeability 
of nano-GOs is much lower than that of GQDs and rGQDs, suggesting that the size may be a 
decisive factor for the BBB permeability of graphene-based nanoparticles (Supplementary Fig. 
13h). Collectively, our results show that GQDs are the optimal therapeutic candidate for anti-PD 
and related α-synucleinopathies therapy with no appreciable in vitro and long-term in vivo 
toxicity, respectable fibril dissociation effects, and the ability to pass through the BBB. 
In order to open new venues in clinical drug development against PD, a candidate 
desirably features outstanding anti-aggregation and dissociation properties towards α-syn 
aggregates without severe toxicity. GQDs are found to bind to α-syn fibrils, inhibit transmission, 
and possess unique neuroprotective effects against the neuropathological α-syn aggregates/fibrils 
in both in vitro and in vivo models. It is expected that GQDs-based drugs with appropriate 
modifications might provide a clue to support the development of new therapeutic agents for 
abnormal protein aggregation related neurological disorders including PD.  
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Methods 
Preparation of GQDs. GQDs were synthesised by putting 0.9 g of carbon fibres (Carbon Make) 
in a mixture of strong acid (300 ml sulphuric acid & 100 ml nitric acid; Samchun Chemical) at 
80 oC for 24 hours. After acid removal, the solution was vacuum-filtered with porous inorganic 
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membrane filter (Cat#: 6809-5002; Whatman-Anodisc 47; GE Healthcare) to discard large 
particles. The solution was then subjected to rotary evaporation to yield the final product in 
powder form. 
FT-IR measurements. The samples prepared through the conventional KBr pellet method 
(Number of scan: 32; Resolution: 4; Wavenumber range: 4000 – 40 cm-1). The analysis was 
performed with a Nicolet 6700 FT-IR spectrometer (Thermo Scientific).  
ThT and Turbidity assays. α-syn fibrils were measured with both turbidity and ThT assays. For 
ThT assay, 50 μl of each sample was centrifuged for 30 mins at 16,000 × g. The pellet was 
resuspended in 200 μl of 25 μM ThT (Cat#: T3516; Sigma-Aldrich) in 10 mM glycine buffer 
(pH 9.0). ThT fluorescence was measured at 482 nm (excitation at 440 nm) by a fluorescence 
spectrophotometer. For turbidity assay, α-syn fibrils were diluted (1/10) with PBS. The diluted 
fibrils were transferred to Corning® 96-well plates and the absorbance intensity at 360 nm was 
measured to assess the turbidity of each sample by microplate multi-reader. 
TEM imaging. For fibrils, samples were adsorbed to glow discharged 400 mesh carbon coated 
copper grids (EMS) for 2 mins. The grids were transferred through three drops of 50 mM Tris-
HCl (pH 7.4) rinse, then floated upon two consecutive drops of 0.75% uranyl formate, each for 
30 secs. Stain was either aspirated or blotted off with #1 Whatman filter paper triangles. Grids 
were allowed to dry before imaging by a Phillips CM 120 TEM operating at 80 kV. Images were 
captured and digitised with an ER-80 CCD (8 megapixel) by AMT. For neurons, primary cortical 
neurons were plated at a density of 100,000 cells/well onto the 35 mm dish coated with poly-D-
lysine. Neurons were treated with 1 μg/ml of PFFs with or without 1 μg/ml of GQDs at days in 
vitro (DIV) 10. After 7-day treatment, neurons were washed with PBS containing 1% sodium 
nitrite (pH 7.4), fixed with fixative consisting of 3% (vol/vol) paraformaldehyde (PFA), 1.5% 
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(vol/vol) glutaraldehyde, 100 mM cacodylate, and 2.5% (vol/vol) sucrose (pH 7.4), and post-
fixed for 1 hour. Images were collected on a Philips EM 410 TEM installed with a Soft Imaging 
System Megaview III digital camera. 
Dot-blot assays. Samples were loaded onto the pre-wetted nitrocellulose membrane (0.45 μm 
pore-sized) using the Bio-Dot microfiltration apparatus (Cat#: 1706545; Bio-Rad) and allowed to 
filter through the membrane under mild vacuum. After washing each sample with Tris-buffered 
saline, samples were blocked with 5% non-fat dry milk in Tris-buffered saline containing tween-
20. Samples were incubated with conformation-specific anti-α-syn filament antibody (Cat#: 
ab209538; 1:1,000; abcam) at 4 oC overnight, followed by HRP-conjugated rabbit secondary 
antibodies (GE Healthcare) for 1 hour at RT. Blots were visualised by ECL solution and 
analysed with ImageJ software (http://rsb.info.nih.gov/ij/,NIH). 
BN-PAGE and SDS-PAGE. For BN-PAGE, α-syn fibrils and α-syn PFFs were prepared using 
NativePAGE™ sample prep kit (Cat#: BN2008; Life technologies) and run on NativePAGE™ 
Novex 4-16% Bis-Tris protein gels (Cat#: BN1002Box; Life technologies) at 200 V for 90 mins. 
The cathode buffer contained 50 mM tricine, 15 mM Bis-Tris, 0.02% Brilliant Blue G (pH 7.0), 
and the anode buffer was consisted of 50 mM Bis-Tris (pH 7.0). Gels were stained using the 
SilverQuest™ silver staining kit (Cat#: LC6070; Life technologies), following the 
manufacturer’s instructions. For SDS-PAGE, 10 DIV cortical neurons were treated with α-syn 
PFFs (5 μg/ml) in the presence and absence of GQDs (5 μg/ml) for 7 days. Soluble proteins of 
neurons were prepared in 1% TX-100 in PBS and protease and phosphatase inhibitor cocktail 
(Cat#: PPC1010; Sigma-Aldrich) at 4 oC. Lysates were sonicated and centrifuged at 12,000 × g 
for 30 mins at 4 oC. The pellet was washed several times and suspended in 2% SDS in PBS for 
insoluble protein preparation. 2× Laemmli sample buffer (Cat#: 1610737; Bio-rad) was utilised 
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to dilute the lysates. Subsequently, 20 μg of proteins were loaded onto the wells of Novex™ 8-
16% Tris-Glycine Gel (Cat#: XP08160BOX; Life technologies) and electrophoresis was 
performed at 130 V for 85 mins. The proteins were then transferred onto nitrocellulose 
membrane, blocked with 5% non-fat dry milk in TBS with 0.1% Tween-20 for 1 hour and 
incubated at 4 oC overnight with anti-pS129-α-syn (Cat#: ab59264; 1:1,000, abcam), SNAP25 
(Cat#: 111-002, 1:2,000, Synaptic Systems) or VAMP2 (Cat#: ab3347; 1:1,000, abcam) 
antibodies, followed by HRP-conjugated rabbit or mouse secondary antibodies (GE Healthcare) 
for 1 hour at RT. Blots were visualised by ECL solution and analysed with ImageJ software 
(http://rsb.info.nih.gov/ij/,NIH). 
Preparation of sonicated α-syn PFFs. α-syn PFFs were prepared according to the previous 
methods reported by Volpicelli-Daley et al21. Mouse recombinant full-length α-syn was cloned 
into the ampicillin-resistant bacterial expression vector pRK172. The plasmids were then 
transformed into BL21(DE3)RIL-competent E. coli (Cat#: 230245; Life technologies). After 
bacterial growth, α-syn monomers were purified through several steps including anion exchange, 
dialysis, and size exclusion chromatography following the instructions of the aforementioned 
literature. In vitro α-syn fibrils were assembled by agitation in an Eppendorf orbital mixer (Cat#: 
538400020) under 7 days of 37 oC incubation at 1,000 rpm. Short fragments of α-syn fibrils were 
achieved simply by sonication at 20% amplitude for a total of 60 pulses (~0.5 seconds each) 
using sonicator with 1/8” probe-sonicator.  
Biotinylation of GQDs and Binding assay. 50 mg of GQDs were dissolved in conjugation 
buffer (pH 4.7) and 12.5 mg of EDC reagent – N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride – (Cat#: 03449; Sigma-Aldrich) were subsequently added to 
replace the carboxyl groups. After 1 hour of reaction with vigorous stirring, 25 mg of EZ-Link 
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Amine-PEG3-Biotin (Cat#: 21347; Thermo Scientific) were added to EDC-activated GQDs. The 
solution was then subjected to dialysis and rotary evaporation to yield the final product in 
powder form. For the binding assay between GQDs and α-syn fibrils, 5 mg/ml of α-syn fibrils 
were incubated with 5 mg/ml of biotinylated GQDs and streptavidin conjugated 0.8 nm ultra-
small gold particles (Cat#: 800.099; Aurion) for 1 hour. Next, the streptavidin conjugated ultra-
small gold particles bound with high affinity to biotinylated-GQDs were enhanced with 
GoldEnhance™ EM Plus solution (Cat#: 2114; Nanoprobes) for 5 mins. Non-reacted solution 
was removed by 100 kDa MWCO spin column (Cat#: UFC510024; Millipore-Sigma), followed 
by TEM analysis. 
Purification of 15N-lablled α-syn. α-syn gene cloned in pRK172 vector was transformed into 
Escherichia coli BL21 (DE3) for α-syn overexpression. For the preparation of isotope-labelled α-
syn, cells were grown in M9 minimal medium containing 0.5 g of 15NH4Cl and 1 g of 
13C 
glucose (Cambridge Isotope Laboratory Inc., Andover, MA) per liter at 37 oC with 100 μg/ml 
ampicillin. After the induction with isopropyl −D-1-thiogalactopyranoside (IPTG), the heat-
treated cell lysate was subjected to successive purifications using DEAE-Sephacel anion-
exchange, Sephacryl S-200 size-exclusion, and S-Sepharose cation-exchange chromatography. 
The purified α-syn was dialysed against 12 L of fresh 20 mM 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer (pH 6.5) three times, and stored in aliquots at a concentration of 1 mg/ml at -
80 ºC. The sample was concentrated to 5 mg/ml using Nanosep 10 K membrane (Pall Gelman, 
Germany) at 4 oC right before the experiments. 
NMR spectroscopy analysis. A detailed NMR study of the interaction between α-syn and 
GQDs was performed using a 950 MHz spectrometer equipped with a cryo-genic probe (Bruker, 
Germany). 15N-lablled α-syn (5 mg/ml, 100 μl) was reacted with GQDs (5 mg/ml, 100 l) under 
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37 oC shaking incubation at 1,000 rpm for 3 days. 15N-labelled α-syn samples were prepared 
using 20 mM MES buffer (pH 6.5) containing 10% for 1H-15N HSQC measurements. 1H-15N 
HSQC spectra of both α-syn and GQDs-reacted α-syn were acquired at 37 oC. Obtained data 
were processed by NMRPipe22 and analysed by Sparky23. 
Simulation details. 200 ns molecular dynamics (MD) simulation was performed with Gromacs 
5.1 to examine the interaction between GQDs and α-syn fibrils at molecular level24. The initial 
structure of hydrophobic NAC domain (residue 71 to 82) of α-syn was adapted from the ssNMR 
structure (PDB ID: 2N0A) with CHARMM forcefield25 and the structure of GQDs was designed 
with CGenFF26 by the protocols of https://cgenff.paramchem.org. 
CD measurements. α-syn fibrils (5 mg/ml, 100 μl) were mixed with GQDs solution (5 mg/ml, 
100 μl), and depolymerised under 37 oC shaking incubation at 1,000 rpm for 7 days. For far-UV 
CD measurements, the sample was diluted (1/2) with DW. The CD spectra between 190 and 260 
nm were measured at 0.5 nm-interval using a J-815 spectropolarimeter (Jasco, Japan) and a 0.2 
mm-path length quartz cuvette. The spectrum of the buffer solution was subtracted from the 
sample spectra. CD signals were normalised to the mean residue ellipticity, [] with the unit of 
deg cm2/dmol. The fractional secondary structure contents of α-syn fibrils and depolymerised α-
syn fibrils were calculated using the algorithm of CONTIN/LL on the DichroWeb online server 
(http://dichroweb.cryst.bbk.ac.uk). For the calculation using CONTIN/LL, reference set 7 on 
Dichroweb was employed, which is optimised for the wavelength range of 190 to 240 nm. 
Primary neuron culture. Primary cortical neurons were cultured using embryonic day 15 
C57BL/6 mice (Charles River). Isolated neurons were plated onto the poly-D-lysine-coated (50 
μg/ml) dishes (Cat#: P6407; Sigma-Aldrich) and placed under the culture medium comprised of 
Neurobasal Media (Cat#: 21103049; Life technologies) with B27 supplement (Cat#: 17504044; 
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Life technologies) and L-glutamine (Cat#: 25030149; Life technologies). The cultures were 
incubated in a 37 oC, 7% CO2 incubator and undergone a half medium change twice a week. To 
prevent glial cell growth, 30 μM 5-fluoro-2’-deocyuridine (Cat#: F0503; Sigma-Aldrich) was 
added after 5 days of culture. All procedures involving mice were approved by and conformed to 
the guidelines of the Johns Hopkins University Animal Care and Use Committee. 
Cell viability and Cytotoxicity assays. For cell viability and cytotoxicity assays, primary 
cortical neurons were plated at a density 10,000 cells/cm2 onto poly-D-lysine coated glass 
coverslip and incubated in 7% CO2 incubator at 37 
oC with a half medium change twice a week. 
Cytotoxicity of primary cultured neurons was determined with α-syn PFFs (1 μg/ml) in the 
absence and presence of GQDs (1 μg/ml) in 10 DIV mouse cortical neurons for 7 days by LDH 
cytotoxicity assay kit (Cat#: 88954, Pierce), following the manufacturer’s instructions. Apoptotic 
cell death was determined using TUNEL assay kit (Cat#: 12156792910; Roche). Primary 
cultured neuronal viability was quantified by alamarBlue cell viability assay kit (Cat#: DAL1025; 
Molecular Probes™) and neurite outgrowth staining kit (Cat#: A15001; Molecular Probes™), 
following the manufacturer’s instructions.  
In vitro immunofluorescence. The mouse primary cortical neurons at a density of 20,000 
cells/cm2 were plated onto poly-D-lysine-coated coverslips. To fix the neurons, 4% PFA was 
used and blocked for 1 hour in a PBS solution containing 5% normal donkey serum (Cat#: 017-
000-121; Jackson ImmunoResearch), 2% bovine serum albumin (Cat#: A7030; Sigma-Aldrich) 
and 0.1% Triton X-100 (Cat#: T8787; Sigma-Aldrich) at RT. Subsequent incubations with anti-
8-OHG (Cat#: ab62623; 1:1,000; abcam), anti-pS129-α-syn (Cat#: ab59264; 1:1,000; abcam) 
and anti-MAP2 (Cat#: MAB3418; 1:1,000; Millipore) antibodies were carried out overnight at 4 
oC. After washing the samples with 0.1% Triton X-100 in PBS, the coverslips were incubated 
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with a mixture of Cy3-conjugated (Donkey anti-mouse CY3; Cat#: 715-165-151, Donkey anti-
rabbit CY3; Cat#: 711-165-152, Jackson ImmunoResearch) and FITC-conjugated (Donkey anti-
mouse FITC; Cat#: 715-095-151, Donkey anti-rabbit FITC; Cat#: 711-095-152, Jackson 
ImmunoResearch) secondary antibodies for 1 hour at RT. The fluorescence images were taken 
through a Zeiss confocal microscope (LSM 710, Zeiss Confocal). 
Microfluidic chambers. Prior to be affixed to the microfluidic devices (triple-chamber 
microfluidic devices, Cat#: TCND1000, Xona), the coverslips were prepared according to the 
previous method5. Each chamber was plated with approximately 100,000 neurons. At DIV 7, 0.5 
μg of GQDs were added to chamber 1 (C1) or chamber 2 (C2) before the treatment of 0.5 μg of 
α-syn PFFs to C1. A 50 μl-difference in media volume was controlled through three 
compartments to regulate the direction of flow. 14 days post-α-syn PFFs treatment, neurons were 
fixed using 4% PFA in PBS. The fixed neurons in chambers were blocked in PBS solution 
containing 5% normal donkey serum, 2% bovine serum albumin and 0.1% Triton X-100 for 1 
hour at RT. Neurons were subsequently incubated with anti-pS129-α-syn (Cat#: ab59264; 
1:1,000; abcam) and anti-MAP2 (Cat#: MAB3418; 1:1,000; Millipore) antibodies for overnight 
at 4 oC. After washing the chambers with 0.1% Triton X-100 in PBS, they were incubated in a 
mixture of FITC-conjugated (Jackson ImmunoResearch) and Cy3-conjugated (Jackson 
ImmunoResearch) secondary antibodies for 1 hour at RT. The fluorescent images were acquired 
through a Zeiss confocal microscope  
Animals. All experimental procedures were followed according to the guidelines of Laboratory 
Animal Manual of the National Institute of Health Guide to the Care and Use of Animals, which 
were approved by the Johns Hopkins Medical Institute Animal Care and Use Committee. The 
human a α-syn-A53T transgenic mice (B6.Cg-Tg; Prnp-SNCA*A53T;23Mkle/J, stock#: 006823) 
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were purchased at the Jackson Lab27. 
Stereological assessments. All experimental procedures were followed according to the 
guidelines of Laboratory Animal Manual of the National Institute of Health Guide to the Care 
and Use of Animals, which were approved by the Johns Hopkins Medical Institute Animal Care 
and Use Committee. C57BL6 mice (8-10 week-old male) were purchased from the Jackson 
laboratories. After anesthetising with pentobarbital (60 mg/kg), mice were stereotaxically 
injected in a designated coordinate of the striatum (+2.0 mm from midline, +2.6 mm beneath the 
dura, +0.2 mm relative to Bregma) with of PBS (2 μl) or PFFs (5 μg/2 μl) (Cat#: Model 900; 
David KOPF instruments). As a treatment, 50 μl of GQDs (50 μg per mouse) were i.p. injected 
for 6 months on a biweekly basis. After 6 months, animals were perfused with PBS and fixed by 
4% PFA for 12 hours. The brains were then subjected to cryoprotection with 30% sucrose. For 
immunohistochemistry, 50 μm coronal sections were cut throughout the brain including the SN. 
Every 4th section was used for analysis and incubated with the rabbit polyclonal anti-TH (Cat#: 
NB300-19; 1:1,000; Novus Biologicals), rabbit polyclonal anti-pS129-α-syn (Cat#: ab59264; 
1:1,000; abcam) with blocking solution. The signals were visualised using DAB kit (Cat#: SK-
4100; Vector Laboratories) followed by incubation with streptavidin-conjugated horseradish 
peroxidase and biotinylated secondary antibodies (Cat#: PK-6101; Vector Laboratories). To 
identify the Nissl substance, the TH-stained tissues were prepared and counterstained with 
thionin on slides. Total number of TH- and Nissl-positive neurons in the SN were counted using 
an Optical Factionator probe of Stereo Investigator software (MBF Bioscience). 
In vivo immunohistochemistry. The brains of animals were perfused with PBS followed by 4% 
PFA. After post-fixation and cryoprotection, sections were stained with anti-Iba-1 (Cat#: 019-
19741; 1:1,000; Wako) or anti-GFAP (Cat#: Z0334; 1:2,000; Dako) antibodies followed by 
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incubation with biotin-conjugated anti-rabbit antibody and ABC reagents (Cat#: PK-6101; 
Vector Laboratories). The sections were developed using DAB peroxidase substrate (Cat#: SK-
4100; Vector Laboratories). The number of microglia and densities of astrocytes in the SN were 
measured with ImageJ software (http://rsb.info.nih.gov/ij/, NIH). For histopathology of the major 
organs, 8-10 week-old male C57BL/6 mice were i.p. injected with 50 μg of GQDs on a biweekly 
basis for 6 months. After 6 months of injection period, animals were perfused with PBS followed 
4% PFA. The liver, kidney, and spleen were isolated and stained with H&E staining kit (Cat#: 
H-3502; Vector Laboratories). 
Behaviour analyses. The cylinder test28: The test was devised to identify any asymmetry in 
forelimb uses. A blinded observer scored every contact made by a forepaw in a 20 cm-wide clear 
glass cylinder from the video clips. A total number of 20 – 30 wall touches were counted per 
animal (only the contacts with fully extended forelimbs). The degree of impaired forelimb 
contacts was quantified as a percentage based on the total forelimb uses. Control group scores 
approximately 50% in this test. The animals were completely isolated from the test cylinder prior 
to the actual testing. No habituation of the animals to the testing cylinder was allowed before 
video recording.  
Pole test29: Test animals were allowed to adapt to the behavioural room for 30 mins 
before actual testing. A 75 cm metal pole with a diameter of 9 mm was prepared with bandage 
gauze wrapping. To initiate the test, each mouse was placed 7.5 cm from the top facing upwards. 
The scores were based on the total time taken to reach the bottom. The test animals were trained 
for two successive days before the actual trial where each practice provided three different trials. 
No more than 60 secs was allowed for each animal. Results for the turn down, climb down, and 
the total time (in sec) were recorded.  
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Statistics. Data were presented as mean ± SD from at least three independent experiments. In 
order to assess the statistical significance, Student’s t tests or ANOVA tests followed by 
Bonferroni post hoc analysis were performed using Prism6 software (GraphPad). Assessments 
with a p < 0.05 were considered significant. 
Data Availability. There is no data relevant to accession codes or unique identifiers non-
publicly available. The data that support the plots within this paper and other findings of this 
study are available from the corresponding authors upon reasonable request.  
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Figure Legends 
Figure 1. The effect of GQDs on α-syn fibrillization and fibril disaggregation. a, Schematic 
representation of the α-syn fibrillization (5 mg/ml α-syn monomers) and disaggregation (5 mg/ml 
α-syn fibrils) in the presence and absence of GQDs (5 mg/ml). b, The kinetics of α-syn 
fibrillization using aliquots of reaction monitored by ThT fluorescence and c, turbidity assays 
(n=4, biologically independent samples; two-way ANOVA with a post hoc Bonferroni test, ***P 
< 0.001; error bars are the standard deviation). The mean values and p values are given in 
Supplementary Table 1. d, TEM images of α-syn after fibrillization in the absence (left) and 
presence (right) of GQDs. e, The kinetics of preformed α-syn fibrils after incubation with GQDs, 
aliquots of reaction monitored by ThT fluorescence and f, turbidity assays at various time points 
(n=4, biologically independent samples; two-way ANOVA with a post hoc Bonferroni test, ***P 
< 0.001; error bars are the standard deviation). The mean values and p values are given in 
Supplementary Table 1. g, Quantifications of the end-to-end length and number of α-syn fibrils. 
Mean values of end-to-end length are 937.84, 245.52, 123.13, 66.27, and 51.02 at 0, 6, 12, 24, 
and 72 hours (n=50 fibrils at each time point; one-way ANOVA with a post hoc Bonferroni test, 
P values are P < 0.0001, P < 0.0001, P < 0.0001, and P < 0.0001 at 6, 12, 24, and 72 hours; error 
bars are the standard deviation). Mean values of number are 15.53, 37.01, 63.83, 97.52, and 
44.38 at 0, 6, 12, 24, and 72 hours (n=6, biologically independent samples; one-way ANOVA 
with a post hoc Bonferroni test, P values are P = 0.0483, P < 0.0001, P < 0.0001, and P = 0.0050 
at 6, 12, 24, and 72 hours; error bars are the standard deviation). h, the amount of remaining α-
syn fibrils determined by multiplying the end-to-end length and number of α-syn fibrils at the 
same time points (0, 6, 12, 24, and 72hours) in the presence of GQDs. Mean values are 100.00, 
47.33, 42.00, 36.67, and 13.83 at 0, 6, 12, 24, and 72 hours (n=6, biologically independent 
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samples; one-way ANOVA with a post hoc Bonferroni test, error bars are standard deviation). i, 
TEM images of preformed α-syn fibrils after various time points (6, 12 hours, 1, 3, and 7days) in 
the absence (top) and presence (bottom) of GQDs. j, Representative image of α-syn fibrils by 
dot-blot assay at various time points (0, 12 hours, 1, 3, and 7 days) with α-syn filament specific 
antibody. These experiments were independently repeated three times with similar results. k, 
BN-PAGE analysis of α-syn, prepared with aliquots of reaction run after various time points (0, 
3, 6 and 12 hours, 1, 3, and 7days). These experiments were independently repeated three times 
with similar results. 
 
Figure 2. Detailed analysis of the interaction between GQDs and mature α-syn fibril during 
the dissociation process. a, TEM images for binding between biotinylated GQDs and α-syn 
fibrils with low and high magnifications. Single-headed arrows indicate the biotinylated GQDs 
enhanced with ultra-small gold-streptavidin nanoparticles. b, Quantifications of the average 
width of α-syn fibrils during the disaggregation process after 1 hour of incubation. Mean  s.d. 
values are 14.74  0.70 and 17.42  0.83 for fibrils and fibrils+GQDs-biotin (n=20 for each 
group, two-tailed Student’s t-test). c, NMR chemical shift difference obtained from full 1H-15N 
HSQC spectra. The decreased intensity ratio of NMR chemical shifts is presented for each 
residue after binding with GQDs. d, The time course simulation dynamics of the interaction 
between GQDs and mature α-syn fibril and 65 ns snapshot image (bottom right) of the 
interaction between GQDs and mature α-syn fibril with designated sidechains attributed for the 
major binding force. e, Time-dependent plots for RMSD of atomic positions, SASA for α-syn 
fibril only group and α-syn fibril and GQDs group, total potential energy (∆Utot), electrostatic 
energy (∆Eelec), and van der Waals energy (∆Evan) for α-syn fibril and GQDs group, respectively 
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from the top. f, Time-dependent secondary structure plot calculated by the DSSP algorithm. g, 
CD spectra of α-syn monomers and α-syn fibrils without and with GQDs after 7 days of 
incubation. h, The fractional secondary structure contents ratio of α-syn fibrils and disaggregated 
α-syn fibrils by GQDs calculated using the algorithm of CONTIN/LL (n=5, biologically 
independent samples). Data are mean  s. d. (fibrils vs fibrils+GQDs; Coil: 20.13  5.74 vs 24.58 
 3.64;  -Turn: 22.39  4.62 vs 25.89  1.34, -Sheet: 53.30  3.53 vs 29.76  3.35; -Helix: 
4.17  1.25 vs 19.74  1.52). 
 
Figure 3. The effect of GQDs on α-syn PFFs-induced neuronal death, pathology and 
transmission in vitro. a. Neuronal death assessed by TUNEL, b, alamarBlue and c, LDH assays 
treated with α-syn PFFs (1 g/ml) in the absence and presence of GQDs (1 g/ml) in 10 DIV 
mouse cortical neurons for 7 days. Mean values of TUNEL are 18.94, 15.86, 61.39, and 30.45 
for PBS, GQDs, PFFs, and PFFs+GQDs; mean values of alamarBlue are 100.00, 99.16, 49.33, 
and 78.86 for PBS, GQDs, PFFs, and PFFs+GQDs; mean values of LDH assay are 100.00, 95.43, 
154.58, and 113.33 for PBS, GQDs, PFFs, and PFFs+GQDs (n=6, biologically independent 
samples; two-way ANOVA with post hoc Bonferroni test; NS, not significant; error bars are the 
standard deviation). d, Representative immunoblot levels with p-α-syn antibody. e, 
Quantifications of the SDS-insoluble fraction normalised to the levels of -actin. Mean values 
are 1.00, 1.49, 16.35, and 6.86 for PBS, GQDs, PFFs, and PFFs+GQDs (n=6, biologically 
independent samples; two-way ANOVA with post hoc Bonferroni test; NS, not significant; error 
bars are the standard deviation). f, Representative p-α-syn immunostaining micrographs with p-
α-syn antibody. g, Quantifications of p-α-syn immunofluorescence intensities normalised to the 
PBS control. Mean values are 1.00, 0.99, 13.62, and 4.69 for PBS, GQDs, PFFs, and 
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PFFs+GQDs (n=6, biologically independent samples; two-way ANOVA with post hoc 
Bonferroni test; NS, not significant; error bars are the standard deviation). h, Schematic 
representation of the microfluidic device for the transmission of pathologic α-syn, composed of 
three connected chambers. i, Representative images of p-α-syn immunostained neurons in the 
microfluidic device after 14 days post α-syn PFFs addition. j, Quantifications of p-α-syn 
immunofluorescence intensities. The areas occupied by p-α-syn were measured in each chamber. 
Mean values of chamber 1 are 15.67, 3.12, and 4.52 for PFFs, PFFs+GQDs (C1), and 
PFFs+GQDs (C2); mean values of chamber 2 are 8.52, 2.56, and 3.90 for PFFs, PFFs+GQDs 
(C1), and PFFs+GQDs (C2); mean values of chamber 3 are 6.04, 1.72, and 1.67 for PFFs, 
PFFs+GQDs (C1), and PFFs+GQDs (C2) (n=6, biologically independent samples; two-way 
ANOVA with post hoc Bonferroni test; NS, not significant; error bars are the standard deviation).  
 
Figure 4. The effect of GQDs on α-syn-induced pathologies in vivo. a, Schematic illustration 
of injection coordinates of α-syn PFFs (5 g) for stereotaxic intra-striatal injection in C57BL/6 
mice. As a treatment, 50 g of GQDs or PBS were i.p. injected biweekly for 6 months. b, 
Representative TH-immunohistochemistry images in the SN of α-syn PFFs-injected hemisphere 
in the absence (top) and the presence (bottom) of GQDs. c, Stereological counting of the number 
of TH- and Nissl-positive neurons in the SN via unbiased stereological analysis after 6 months of 
α-syn PFFs injection with and without GQDs injection. Mean values are 5061, 5096, 3155, and 
4080 for Nissl-positive neurons; 4039, 4068, 2327, and 3221 for TH-positive neurons (n=6, 
biologically independent animals; two-way ANOVA with a post hoc Bonferroni test; NS, not 
significant; error bars are the standard deviation). d, Representative TH-immunohistochemistry 
images in the striatum of α-syn PFFs-injected hemisphere. e, Quantifications of TH-
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immunopositive fibre densities in the striatum. Mean values are 1.00, 1.03, 0.42, and 0.90 for 
PBS+PBS, PBS+GQDs, PFFs+PBS, and PFFs+GQDs (n=6, biologically independent animals; 
two-way ANOVA with a post hoc Bonferroni test; NS, not significant; error bars are the standard 
deviation). f, Assessments of the behavioural deficits measured by the use of forepaws in the 
cylinder test. Mean values are 51.00, 51.67, 29.83, and 44.17 for PBS+PBS, PBS+GQDs, 
PFFs+PBS, and PFFs+GQDs (n=6, biologically independent animals; two-way ANOVA with a 
post hoc Bonferroni test; NS, not significant; error bars are the standard deviation). g, 
Assessments of the behavioural deficits measured by the ability to grasp and descend from a pole. 
Mean values are 10.25, 11.38, 22.73, and 14.43 for PBS+PBS, PBS+GQDs, PFFs+PBS, and 
PFFs+GQDs (n=6, biologically independent animals; two-way ANOVA with a post hoc 
Bonferroni test; NS, not significant; error bars are the standard deviation). h, Representative p-α-
syn immunostaining images in the striatum and SN of α-syn PFFs-injected hemisphere. i, 
Quantifications of p-α-syn immunoreactive neurons in the striatum and SN. Mean values are 
43.33 and 12.50 for PFFs+PBS and PFFs+GQDs of striatum (STR); 17.67 and 8.00 for 
PFFs+PBS and PFFs+GQDs of SN (n=6, biologically independent animals; two-tailed Student’s 
t-test; error bars are the standard deviation). j, Distribution of LB/LN-like pathology in the CNS 
of α-syn PFFs-injected hemisphere (p-α-syn positive neurons; red dots, p-α-syn positive neurites; 
red lines). 
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